Patent · US Active

Substituted quinazolin-4-ones for inhibiting ubiquitin specific protease 7

US9546150B2 · kind B2 · utility

26Cited by
5References
23Claims
0Family size

Assignee

Inventors

Key dates

Filing dateAug 29, 2012
Grant dateJan 17, 2017
Priority date
Expiry dateAug 29, 2032

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07D409/14
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention relates to quinazolin-4-one compounds of formula (I′), their process of preparation and uses thereof. These compounds are useful as selective and reversible inhibitors of ubiquitin specific proteases, particularly USP7, for treating e.g. cancer, neurodegenerative diseases, inflammatory disorders and viral infections.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.